The Traderszone Network

Published in TZ Latest News 7 November, 2017 by The TZ Newswire Staff

Why Supernus Pharmaceuticals Inc. Is Having a Rather Non-Super Day

Shares of Supernus Pharmaceuticals (NASDAQ: SUPN), a developer of drugs that target diseases of the central nervous system, plunged as much as 19% during Tuesday’s trading session following the release of its third-quarter operating results after the closing bell on Monday. While the company’s third-quarter report looked stellar on paper, cost concerns and a possible guidance misunderstanding appears to be the root cause of today’s damage.

read more